特瑞普利单抗联合一线化疗治疗晚期胃癌的疗效及对患者肿瘤标志物的影响  

Efficacy of toripalimab combined with first-line chemotherapy in the treatment of advanced gastric cancer patients and its influence on tumor markers

作　　者：王珍珍[1] 李丽[1] 陈彦民 付培彪 侯晶晶 吕晶晶[1] WANG Zhenzhen;LI Li;CHEN Yanmin;FU Peibiao;HOU Jingjing;LYU Jingjing(Department of Oncology,the Second People’s Hospital of Jiaozuo,Jiaozuo 454000,He’nan,China)

机构地区：[1]焦作市第二人民医院肿瘤内科,河南焦作4540000

出　　处：《癌症进展》2025年第9期1073-1076,共4页Oncology Progress

摘　　要：目的探讨特瑞普利单抗联合一线化疗治疗晚期胃癌的疗效及对患者肿瘤标志物的影响。方法依据治疗方式的不同将107例晚期胃癌患者分为对照组(n=54)和观察组(n=53),对照组患者接受替吉奥+奥沙利铂(SOX)方案治疗,观察组患者接受特瑞普利单抗联合SOX方案治疗。比较两组患者的临床疗效、肿瘤标志物[糖类抗原(CA)72-4、CA19-9、癌胚抗原(CEA)]水平、T淋巴细胞亚群(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平及不良反应发生情况。结果观察组患者的治疗总有效率为47.17%,高于对照组患者的27.78%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CEA、CA19-9、CA72-4水平均低于本组治疗前,观察组CEA、CA19-9、CA72-4水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD4^(+)水平及CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,观察组患者CD4^(+)水平及CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。两组患者骨髓抑制、胃肠道反应、神经毒性、肝脏异常发生率比较,差异均无统计学意义(P﹥0.05)。结论特瑞普利单抗联合SOX方案治疗晚期胃癌患者的效果显著,可降低血清肿瘤标志物水平,改善T淋巴细胞亚群水平,且不增加不良反应。Objective To investigate the efficacy of toripalimab combined with first-line chemotherapy in the treatment of advanced gastric cancer patients and its influence on tumor markers.Method According to different treatment methods,107 patients with advanced gastric cancer were divided into control group(n=54)and observation group(n=53).Patients in the control group received S-1+oxaliplatin(SOX)regimen treatment,while patients in the observation group received toripalimab combined with SOX regimen treatment.The clinical efficacy,tumor markers[carbohydrate antigen(CA)72-4,CA19-9,carcinoembryonic antigen(CEA)]levels,T lymphocyte subsets(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))levels,and incidence of adverse reactions were compared between the two groups.Result The total effective rate of treatment in observation group was 47.17%,which was higher than 27.78%in control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CEA,CA19-9,and CA72-4 in both groups were lower than those before treatment,the levels of CEA,CA19-9,and CA72-4 in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).After treatment,the CD4^(+)and CD4^(+)/CD8^(+)levels in both groups were higher than those before treatment,while the CD8^(+)levels were lower than those before treatment,the CD4^(+)and CD4^(+)/CD8^(+)levels in observation group were higher than those in control group,while the CD8^(+)level was lower than that in control group,and the differences were statistically significant(P<0.05).There were no statistically significant differences in the incidences of bone marrow suppression,gastrointestinal reactions,neurotoxicity,and liver abnormalities between the two groups of patients(P>0.05).Conclusion Toripalimab combined with SOX regimen chemotherapy has significant efficacy in the treatment of advanced gastric cancer patients,which can reduce the serum tumor marker levels,improve T lymphocyte subset levels,and does not increase adverse reactions.

关 键 词：胃癌 特瑞普利单抗 一线化疗 肿瘤标志物 

分 类 号：R735.2[医药卫生—肿瘤]